Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-Current Debt: 2019-2024

Historic Non-Current Debt for Tg Therapeutics (TGTX) over the last 6 years, with Dec 2024 value amounting to $244.4 million.

  • Tg Therapeutics' Non-Current Debt rose 0.48% to $245.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.3 million, marking a year-over-year increase of 0.48%. This contributed to the annual value of $244.4 million for FY2024, which is 144.14% up from last year.
  • According to the latest figures from FY2024, Tg Therapeutics' Non-Current Debt is $244.4 million, which was up 144.14% from $100.1 million recorded in FY2023.
  • Tg Therapeutics' Non-Current Debt's 5-year high stood at $244.4 million during FY2024, with a 5-year trough of $7.7 million in FY2020.
  • For the 3-year period, Tg Therapeutics' Non-Current Debt averaged around $138.6 million, with its median value being $100.1 million (2023).
  • As far as peak fluctuations go, Tg Therapeutics' Non-Current Debt plummeted by 73.37% in 2020, and later spiked by 765.58% in 2021.
  • Over the past 5 years, Tg Therapeutics' Non-Current Debt (Yearly) stood at $7.7 million in 2020, then soared by 765.58% to $66.8 million in 2021, then increased by 6.51% to $71.1 million in 2022, then spiked by 40.74% to $100.1 million in 2023, then skyrocketed by 144.14% to $244.4 million in 2024.